Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM512 in moderate-to-severe asthma
CTR20252182Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM512 in asthma, sponsored by Keymed Biosciences. Started Aug 2025; status: active.
02
Drugs
CM512
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20252182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252182.